{"id":"W4396939418","doi":"10.1016/j.isci.2024.109978","title":"CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer","year":2024,"lang":"en","type":"article","venue":"iScience","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sierra Wireless (Canada)","funders":"Cancer Council Queensland; Cancer Council NSW; National Health and Medical Research Council; Cancer Council South Australia; Medical Research Council; Cancer Council Tasmania; National Institutes of Health; Cooperative Research Centres, Australian Government Department of Industry; Cancer Council Victoria; Eisai; Australian Centre for Geomechanics; Sierra Oncology; University of Melbourne; Clovis Oncology; BeiGene; Australian Government; Medical Research and Materiel Command; Victorian Cancer Agency; University of Pennsylvania; Johns Hopkins University; AstraZeneca","keywords":"Ovarian cancer; PARP inhibitor; Cancer research; Chemistry; Medicine; Cancer; Poly ADP ribose polymerase; Internal medicine; DNA; Biochemistry; Polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003501024,0.0001987616,0.0002737779,0.0002768708,0.0001139885,0.0001175753,0.0001211161,0.0001064023,0.0003785471],"category_scores_gemma":[0.00006002668,0.0001686047,0.00005603589,0.001006459,0.0003887511,0.0003455964,0.00006639502,0.0003396123,0.00005214017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004151447,"about_ca_system_score_gemma":0.0005340516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004512832,"about_ca_topic_score_gemma":0.0002244254,"domain_scores_codex":[0.9980299,0.00004104866,0.0003189634,0.0007053154,0.0004919857,0.0004127896],"domain_scores_gemma":[0.9992644,0.0001037,0.00005652602,0.0002969922,0.00007525591,0.000203128],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001373694,0.0002415874,0.006224057,0.0004164293,0.00007601585,0.0005216752,0.01521793,0.00001442082,0.8316736,0.003492452,0.03099508,0.1097531],"study_design_scores_gemma":[0.004959813,0.0007267612,0.09819333,0.004558078,0.00008391465,0.0001572061,0.001661268,0.001478525,0.6147012,0.00464891,0.2679019,0.0009291008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9670103,0.007653509,0.0002537639,0.01674184,0.001420525,0.000649739,0.0001237142,0.0001696258,0.005977001],"genre_scores_gemma":[0.9947446,0.0005401648,0.0003478164,0.002128475,0.0005328152,0.0001476696,0.000003654492,0.00002588069,0.001528922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2369068,"threshold_uncertainty_score":0.68755,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0326593061972015,"score_gpt":0.3409201649224782,"score_spread":0.3082608587252766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}